Sanofi

How is AI speeding up drug discovery? AI for R&D — From lab to life-changing treatment, AI is revolutionizing how we discover and develop medicines. In Chapter 2 of our “AI at Sanofi” series, we explore how AI is accelerating our efforts to bring breakthrough medicines to patients — helping science move faster, decisions get smarter, and therapies reach patients sooner. ✨ Accelerate drug discovery from years to months 🎯 Design treatments tailored to individual biology 🔬 Transform weeks of research into hours 💡 Push the boundaries of what's possible in medicine 🎥 Watch the new video! #DrugDiscovery #AIinHealthcare #DigitalTransformation

If you’re chasing your dreams, don’t stop, we’re right beside you. We’re chasing the miracles of science for those who need it most. A life defined by family, a dedicated career, and a battle against a disease her father also fought. Despite living with COPD, Géraldine still chases her dreams. Explore Géraldine's inspiring story and more here: http://spkl.io/6049AdpZc

Think #flu is no big deal? The World Health Organization’s flu vaccination coverage target for older adults is 75%. Our #Flunomics report reveals that most countries analyzed fell well below the coverage target – leading to high costs and greater strain on national care systems. This report is not just about flu. It is about building smarter, more tailored preparedness to better support those that need it most – older adults. ➡️ Discover the full report: http://spkl.io/6043AjkaZ

#NEWS: The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of our disease modifying therapy for stage 2 autoimmune #T1D. This recommendation brings us one step closer to being able to provide a new class of treatment for people living with this condition in the European Union. Read our press release: http://spkl.io/6049Ajn43

On World Diabetes Day, we join the International Diabetes Federation (IDF) in highlighting this year’s theme: ‘Diabetes and the workplace’. Diabetes is one of the most pressing health challenges of our time, experienced by 589 million people worldwide and shaping lives far beyond the clinic. According to the IDF, seven in 10 people living with diabetes are of working age, underscoring the urgent need for greater awareness and supportive environments for people living with diabetes. But living with diabetes doesn't mean putting your dreams on hold, many continue to thrive in their careers and personal lives. At Sanofi, we’re committed to going beyond treatment, combining education, innovative therapies, and holistic support to help people living with diabetes lead healthier, fuller lives. Learn more about our efforts to enhance diabetes care here: http://spkl.io/6046Ajy4u #WDD2025 #Diabetes #WorldDiabetesDay Kathi Korn

📈 #MultipleSclerosis (MS) represents a major economic challenge all over the world, with per-person costs ranging from $57,140 (UK) to $145,857 (US) per year. New research from Economist Impact, which we supported, delivers a crucial message for those shaping healthcare policy: 📊 Better understanding of the economic and societal challenges posed by MS-related disability is critical to improving holistic care for people living with MS. Read more ➡️ http://spkl.io/6042Aj3Ou #HealthPolicy #PublicHealth Research commissioned by Sanofi. All editorial control retained by Economist Impact.

The GBS|CIDP Foundation International—made up of global experts, advocates, and people living with Chronic Inflammatory Demyelinating Polyneuropathy (#CIDP)—is working to create a shared language for the community. The way we describe symptoms, progress, or setbacks can shape everything from clinical trials to daily care conversations. Dr. Jeffrey Allen, MD, Associate Professor of Neurology at the University of Minnesota, shares how this collective push for consistent terminology aims to support research, treatment, and patient empowerment. When we speak the same language, we build stronger connections and a more supportive community for patients living with CIDP. Learn more ⤵️ http://spkl.io/6045AbhKS

Diagnosed with multiple sclerosis at 30, Céline transformed her life. She left her career to become a two-time world champion in para surfing, adapting her sport and life with incredible resilience. Her dream? To represent France at the highest level. 🌊 Céline's story is a powerful reminder that with scientific progress and an unwavering spirit, extraordinary things are possible. We're chasing the miracles of science so you can chase your dreams! Discover more inspiring stories like Céline’s: http://spkl.io/6047AbNOV #FutureOfMedicine #ScienceForLife #EmpoweredByScience

Accessibility drives innovation. Innovation drives progress. At our Access Ahead Forum in Paris, we convened global partners and experts to explore how inclusive design creates better solutions for everyone. From AI-enabled tools to adaptive technologies, the conversations reinforced a powerful truth: when we design for accessibility, we unlock potential for all. Accessibility isn't a checkbox—it's a catalyst. It's how we build workplaces and healthcare systems where everyone can belong, contribute, and thrive. Together, we're chasing the miracles of science by ensuring no one is left behind. 💜 #AccessAhead #SanofiIncForum2025 Valuable 500

This November we recognize COPD Awareness Month, an important time to shed light on a disease that impacts almost sixteen million patients in the U.S. who live with chronic obstructive pulmonary disease (COPD). At Sanofi, we remain committed to advancing research in COPD, continuing to push boundaries in our pursuit of improving the daily lives of patients living with this difficult disease. To learn more about COPD, visit http://spkl.io/6041AbggB #COPDAwarenessMonth #COPDAwareness